Norepinephrine Reuptake Inhibitors (NRIs) are drugs that function primarily by inhibiting the reuptake of the neurotransmitter norepinephrine (noradrenaline) and/or epinephrine (adrenaline). Inhibiting the reuptake of norepinephrine tends to elicit stimulating effects, thereby increasing both cortical arousal and energy levels. The NRI drugs are typically prescribed to individuals that may benefit from increased arousal such as …
In recent years, biotech and pharmaceutical companies have been developing new classes of antidepressants. These new classes attempt to improve on older classes of medication in regards to efficacy, side effects, and tolerability. One such class that is being developed is that which targets opioid receptors, particularly the kappa receptor. These drugs are classified as …
The quest to come up with a superior antidepressant is in full effect among biotech and pharmaceutical companies. Although there are some companies that are still tweaking various formulations of serotonergic, noradrenergic, and dopaminergic substances (e.g. triple reuptake inhibitors) others are thinking outside the box. Based on current trends, the next decade or two of …
Scientists and mental health researchers have long been collecting evidence to discover what causes depression. Their goal is to find a specific neurotransmitter or system that could be targeted to develop a new class of antidepressant medication that would be more effective for the masses, result in less side effects, and be considered safe. While …
NRX-1074 is a new antidepressant under development by the biotech company Naurex. It is this same company that has already been granted “fast track” status by the FDA for their intravenous antidepressant GLYX-13 – which shows significant promise. Naurex’s private stock has been steadily rising due to emergence of preliminary evidence suggesting that both of …
A new antidepressant chemically named “GLYX-13” was developed by the biotech company Naurex for individuals with treatment-resistant depression. It is currently in clinical trials as an antidepressant augmentation strategy, meaning it is used as an add-on to already approved treatments. However, most evidence would suggest that it works extremely well as a standalone treatment option. …
It’s blatantly obvious that psychiatry is an imperfect practice. These days people often seek the help of a psychiatrist with the belief that a pill can be prescribed to essentially cure a disease or get symptoms of a mental illness under control. While psychiatry can offer many benefits in the treatment of certain conditions, especially …